Insilico Medicine's ISM5411, an AI-designed gut-restricted PHD inhibitor, demonstrates favorable safety and tolerability in Phase I trials for inflammatory bowel disease (IBD).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.